WASHINGTON (Aug. 25, 2023)-- The U.S. Preventive Services Task Force issued its recommendations on August 22 to expand the coverage of a group of medications known as PrEP, or pre-exposure prophylaxis, which are taken to prevent HIV. The recommendation will require private insurers to cover the expansion of PrEP drugs without a co-pay or deductible under the Affordable Care Act. Earlier this year, a federal judge in Texas struck down the ACA requirement that employers cover preventive health care services that had been earlier recommended by the task force. The Biden Administration has appealed the decision.
The George Washington University has experts that can talk about medical insurance coverage of PrEP, or HIV prevention. To schedule an interview, please contact Rachel Larris at [email protected].
Manya Magnus is professor & interim Chair of the Department of Epidemiology at the George Washington University Milken Institute School of Public Health. She is the principal investigator of the DC Clinical Trials Unit and her research focuses on prevention of HIV, including participating in multi-site clinical trials of biomedical prevention and treatment interventions.
Marc Siegel is a professor of medicine and Director of the Division of Infectious Diseases at the GW School of Medicine & Health Sciences. His areas of clinical interest include PrEP and novel therapies for treatment of HIV. He is currently the principal investigator for the DC Clinical Trials Unit of a study looking at a long-acting injectable HIV medication to prevent HIV in women at risk.
Amanda Castel is a professor of epidemiology at the GW Milken Institute School of Public Health, and a nationally recognized expert in HIV/AIDS prevention, care and treatment. She has also served on NIH's AIDS Research Advisory Council.